Literature DB >> 12057865

A myeloperoxidase polymorphism associated with reduced risk of lung cancer.

Matthew B Schabath1, Margaret R Spitz, Waun K Hong, George L Delclos, Wanda F Reynolds, Gary B Gunn, Lawrence W Whitehead, Xifeng Wu.   

Abstract

Myeloperoxidase (MPO) is a metabolic/oxidative enzyme found in neutrophils and monocytes that contributes to pulmonary carcinogenesis through activation of specific procarcinogens including benzo[a]pyrene intermediates, 4-aminobiphenyl and the arylamines. There is a G-->A polymorphism located in the 5' untranslated region of the MPO gene that may be responsible for reduced transcriptional activity due to the decreased binding affinity for the SP1 transcription factor. Individuals with one or two copies of the A-allele may be afforded protection due to decreased transcriptional activity of MPO and subsequent decreased metabolic activation of procarcinogens. Previous studies have reported a range of protective effects in different ethnic populations. We employed a restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) assay to identify the MPO genotypes in 375 lung cancer cases and 378 healthy controls, all of whom were Caucasian. Our results demonstrate a reduced risk of lung cancer when the A-allele genotypes (G/A+A/A) were combined (odds ratio (OR)=0.66; 95% confidence interval (CI) 0.49-0.90). We also noted a protective effect (OR=0.63; 95% CI 0.45-0.87) in ever smokers with the A-allele genotypes which was not evident in never smokers (OR=1.14; 95% CI 0.42-3.11). We observed an incremental decrease in the protective effects as cigarette pack-years increased. Thus, lightest smokers were provided the greatest protection. When the data were stratified by gender, there was a statistically significant reduced risk of lung cancer among men (OR=0.55; 95% CI 0.36-0.84), but not among women (OR=0.81; 95% CI 0.55-1.26) for the A-allele genotypes. Lastly, an age effect was evident only in men but not women. The protective effects of the A-allele genotypes decreased with increasing age. This report provides further support for the hypothesis that a single nucleotide polymorphism in the MPO gene is a protective factor in lung cancer carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057865     DOI: 10.1016/s0169-5002(02)00034-x

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  19 in total

1.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

2.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

3.  Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Liang Song; Ling Peng; Zhibin Bu; Sen-Xiang Yan; Jie Feng; Xin-Li Zhu; Xin-Biao Liao; Xue-Lin Yu; Danfang Yan
Journal:  Mol Genet Genomics       Date:  2014-10-22       Impact factor: 3.291

4.  Quantitative assessment of the influence of common variations on 6p21 and lung cancer risk.

Authors:  Jicheng TanTai; Yuzhou Shen; Heng Zhao
Journal:  Tumour Biol       Date:  2014-01

5.  HapMap-based study on the association between MPO and GSTP1 gene polymorphisms and lung cancer susceptibility in Chinese Han population.

Authors:  Jun-dong Gu; Feng Hua; Chao-rong Mei; De-jie Zheng; Guo-fan Wang; Qing-hua Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

6.  A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.

Authors:  Chunyan He; Rulla M Tamimi; Susan E Hankinson; David J Hunter; Jiali Han
Journal:  Breast Cancer Res Treat       Date:  2008-03-14       Impact factor: 4.872

7.  Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.

Authors:  Richard A Maki; Vladimir A Tyurin; Robert C Lyon; Ronald L Hamilton; Steven T DeKosky; Valerian E Kagan; Wanda F Reynolds
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

8.  Genetic Polymorphisms of CYP2E1, GSTP1, NQO1 and MPO and the Risk of Nasopharyngeal Carcinoma in a Han Chinese Population of Southern China.

Authors:  Xiuchan Guo; Yi Zeng; Hong Deng; Jian Liao; Yuming Zheng; Ji Li; Bailey Kessing; Stephen J O'Brien
Journal:  BMC Res Notes       Date:  2010-07-27

Review 9.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

10.  Association of myeloperoxidase with ovarian cancer.

Authors:  Dan Cacsire Castillo-Tong; Dietmar Pils; Georg Heinze; Ioana Braicu; Jalid Sehouli; Alexander Reinthaller; Eva Schuster; Andrea Wolf; Rafal Watrowski; Richard A Maki; Robert Zeillinger; Wanda F Reynolds
Journal:  Tumour Biol       Date:  2013-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.